Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
•
premenopausal
•
mammaprint
•
pt3
Would a low genomic Mammaprint score deter you from offering adjuvant chemotherapy to a premenopausal woman with pT3N0 breast cancer?
Related Questions
How would you manage a young premenopausal woman with hormone receptor-positive micrometastatic breast cancer in two axillary lymph nodes, but with only DCIS on breast surgical pathology?
Would you consider anthracycline based neoadjuvant therapy for ER negative, HER2 positive inflammatory breast cancer in a premenopausal female given the subset not adequately represented in non-anthracycline regimen trials?
When do you recommend preoperative chemotherapy or hormonal therapy for ER+ breast cancer?
What are your top takeaways in Radiation Oncology from SABCS 2024?
Given the HELEN-006 trial results, under what circumstances, if any, would you consider de-escalated neoadjuvant therapy in HER2-positive breast cancer?
Would you offer adjuvant endocrine therapy for a postmenopausal female with stage III triple positive multicentric breast cancer (DCIS and invasive ductal carcinoma) s/p neoadjuvant TCHP followed by bilateral mastectomy with no residual disease?
How do the results of INSEMA and SOUND impact the decision of omitting SLND in young women with breast cancer and offering adjuvant RT to patients who would otherwise be candidates for omission?
Would history of breast cancer deter you from using ospemifene for severe vaginal dryness/dyspareunia?
What are your top takeaways in Medical Oncology from SABCS 2024?
Do you routinely check hormone levels to confirm postmenopausal status before adding aromatase inhibitors to OFS in premenopausal women with early breast cancer?
